Saturday 17 October 2026
Export ARWR’s income statement to Excel — free account
Arrowhead Pharmaceuticals, Inc.
ARWR Healthcare Biotechnology
Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024. In the quarter to June 2026, revenue grew 171.0%, EPS fell 7.94%, free cash flow fell 15.4% and total debt rose 259.5%, each against the same quarter a year earlier.
55.90
2.60
−4.44%
Follow ARWR
| Sep '25 | Sep '24 | Sep '23 | Sep '22 | Sep '21 | Sep '20 | Sep '19 | Sep '18 | Sep '17 | Sep '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
5 | 3 | 2 | 3 | 4 | 1 | 6 | 3 | 4 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 40.84 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
2.98 | (1.64) | 1.64 | 5.94 | 11.53 | 41.73 | 14.96 | 51.86 | 2.16 | 2.27 |
P/S ratio |
5.56 | 12.77 | 11.64 | 14.33 | 46.84 | 49.29 | 15.67 | 99.53 | 10.47 | 2,831.07 |
Altman Z″-Score (non-manufacturers) |
0.82 | (4.57) | (2.87) | (1.47) | (0.75) | 7.18 | 2.84 | (7.59) | (9.18) | (8.09) |
P/FCF ratio |
29.41 | 0.00 | 0.00 | 0.00 | 43.84 | 0.00 | 16.42 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
225.14 | (16.91) | (108.08) | (50.69) | (269.54) | (385.18) | 191.52 | (599.44) | (35.73) | (44.07) |
Beneish M-Score |
— | — | — | (3.10) | 1.91 | (1.40) | 3.64 | 4.36 | 172.45 | — |
P/B ratio |
9.16 | 12.14 | 9.76 | 8.33 | 15.84 | 9.39 | 10.84 | 16.87 | 4.07 | 4.72 |
Price to Tangible BV |
9.29 | 12.71 | 10.12 | 8.57 | 16.39 | 9.72 | 11.65 | 21.01 | 5.44 | 6.16 |
EV/Sales |
4.76 | 11.24 | 11.56 | 13.11 | 44.36 | 45.94 | 14.15 | 94.92 | 8.46 | 2,308.47 |
EV/EBITDA |
33.90 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 35.81 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
21.99 | (4.41) | (18.08) | (23.43) | 35.81 | (42.20) | 13.80 | (32.45) | (11.09) | (5.68) |
EV/FCF |
25.17 | (3.38) | (8.41) | (16.88) | 41.52 | (37.52) | 14.83 | (31.50) | (8.34) | (5.36) |
Quick Ratio |
4.74 | 6.60 | 3.83 | 2.72 | 2.58 | 7.78 | 2.67 | 6.22 | 3.51 | 3.33 |
Current Ratio |
4.86 | 6.74 | 3.95 | 2.92 | 2.62 | 7.92 | 2.73 | 6.37 | 3.63 | 3.53 |
Net Debt/EBITDA |
(5.70) | 0.49 | 0.10 | 1.78 | 2.44 | 3.40 | (3.88) | 1.46 | 1.95 | 1.06 |
Debt/Assets |
18.40% | 34.50% | 50.09% | 11.79% | 3.60% | 4.05% | 0.00% | 2.08% | 2.44% | 2.13% |
Debt/Equity |
0.51 | 2.06 | 1.34 | 0.20 | 0.06 | 0.05 | 0.00 | 0.02 | 0.03 | 0.03 |
Asset Turnover |
0.66 | 0.00 | 0.33 | 0.35 | 0.22 | 0.20 | 0.73 | 0.15 | 0.27 | 0.00 |
Operating CF/Net income |
(110.09) | 0.77 | 0.75 | 0.77 | (1.22) | 1.13 | 2.55 | 0.87 | 0.70 | 0.79 |
Capex/Depreciation |
(1.25) | (9.22) | (16.87) | (3.96) | (2.76) | (1.85) | (2.18) | (0.28) | (1.70) | (1.11) |
Interest Coverage |
1.10 | (18.58) | (11.19) | (35.47) | (24.35) | (10.14) | 8.79 | (53.35) | (89.13) | (307.53) |
| (0.47%) | (250.72%) | (58.19%) | (42.57%) | (32.36%) | (23.96%) | 40.07% | (61.84%) | (39.09%) | (79.87%) | |
| (0.13%) | (62.93%) | (28.17%) | (25.11%) | (22.85%) | (19.39%) | 29.46% | (50.50%) | (29.61%) | (62.76%) | |
ROIC |
0.00% | 0.00% | (47.98%) | (90.32%) | (139.91%) | (34.78%) | 0.00% | (166.22%) | (129.96%) | (412.49%) |
Return on Tangible Assets |
(0.14%) | (61.28%) | (34.14%) | (46.73%) | (49.12%) | (27.05%) | 35.52% | (67.78%) | (53.13%) | (101.84%) |
Average Days of Receivables |
3.00 | 0.00 | 0.00 | 2.12 | 27.07 | 3.51 | 1.43 | 7.40 | 0.79 | 172.93 |
Research and Development Expense of Revenue |
73.20% | 14,245.85% | 146.71% | 122.23% | 149.21% | 146.46% | 48.02% | 328.13% | 162.08% | 39,240.56% |
Selling, General and Administrative Expense of Revenue |
14.94% | 2,781.22% | 38.44% | 51.16% | 58.56% | 59.41% | 15.73% | 118.39% | 55.72% | 14,905.18% |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.02 | 0.02 | 0.03 | 0.05 | 0.17 | 0.20 | 0.17 |
Share Based Compensation of Revenue |
7.64% | 2,083.02% | 32.45% | 49.70% | 55.44% | 49.30% | 7.34% | 52.38% | 25.13% | 7,325.21% |
Graham Net Nets |
0.01 | (0.11) | (0.02) | 0.04 | 0.01 | 0.06 | 0.06 | 0.04 | 0.14 | 0.13 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.35 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(0.23%) | (25.92%) | (7.35%) | (5.08%) | (2.18%) | (1.95%) | 2.45% | (3.44%) | (10.34%) | (18.10%) |
Free Cash Flow Yield |
3.40% | (26.05%) | (11.80%) | (5.42%) | 2.28% | (2.48%) | 6.09% | (3.03%) | (9.69%) | (15.22%) |
Revenue per Share |
6.20 | 0.03 | 2.26 | 2.31 | 1.33 | 0.87 | 1.80 | 0.19 | 0.43 | 0.00 |
Operating CF per Share |
1.34 | (3.86) | (1.44) | (1.29) | 1.65 | (0.95) | 1.84 | (0.56) | (0.32) | (1.06) |
Capex per Share |
(0.17) | (1.18) | (1.66) | (0.50) | (0.23) | (0.12) | (0.13) | (0.02) | (0.11) | (0.06) |
Free Cash Flow per Share |
1.17 | (5.05) | (3.10) | (1.79) | 1.42 | (1.07) | 1.72 | (0.58) | (0.43) | (1.12) |
Cash per Share |
6.87 | 5.68 | 3.78 | 3.57 | 3.55 | 3.13 | 2.76 | 0.92 | 0.89 | 1.40 |
Shareholders Equity per Share |
3.76 | 1.60 | 2.69 | 3.97 | 3.94 | 4.58 | 2.60 | 1.14 | 1.09 | 1.56 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
3.76 | 1.60 | 2.69 | 3.97 | 3.94 | 4.58 | 2.60 | 1.14 | 1.09 | 1.56 |
Free Cash Flow |
156.89 | (604.32) | (330.63) | (188.91) | 147.75 | (107.75) | 161.03 | (48.64) | (31.86) | (68.29) |
Working Capital |
755.15 | 592.30 | 311.02 | 266.45 | 238.06 | 281.69 | 168.18 | 66.40 | 49.20 | 64.86 |
Capital Expenditures |
(22.67) | (141.47) | (176.74) | (52.78) | (23.57) | (11.95) | (12.00) | (1.42) | (7.92) | (3.86) |
Net Current Asset Value |
68.76 | (253.27) | (61.92) | 131.70 | 83.27 | 261.65 | 159.44 | 62.40 | 44.75 | 57.35 |
EV/EBIT |
40.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.03 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 39.84 | 0.73 | 0.22 | 0.17 | 0.14 | 0.07 | 0.09 | 0.25 | 24.39 |
Price to Operating Income |
46.91 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.22 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.05 | 0.04 | 0.04 | 0.12 | 0.18 | 0.21 | 0.24 | 0.36 | 0.30 | 0.23 |
Cash ROIC |
9.35% | (47.76%) | (30.78%) | (21.56%) | 18.42% | (13.50%) | 32.03% | (27.94%) | (21.38%) | (37.29%) |
Accounts Receivable Turnover |
201.47 | 0.00 | 0.00 | 41.70 | 24.91 | 116.75 | 341.42 | 81.69 | 439.88 | 2.11 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | 0.00 | 0.00 | — | — | — | — | — | — |
Average Receivables |
4.12 | — | — | 5.83 | 5.55 | 0.75 | 0.49 | 0.20 | 0.07 | 0.08 |
Average Payables |
14.53 | 23.63 | 19.37 | 6.16 | 8.14 | 7.24 | 5.23 | 3.44 | 8.15 | 8.63 |
Average Assets |
1,262.55 | 952.68 | 728.75 | 701.04 | 616.33 | 436.17 | 230.73 | 107.82 | 116.10 | 130.22 |
Average Common Equity |
347.24 | 239.11 | 352.75 | 413.58 | 435.30 | 352.91 | 169.64 | 88.05 | 87.95 | 102.32 |
Columns are period end dates